Kickback, bribery and racketeering charges are followed by a CRL for opioid spray at scandal-plagued Insys
Over the past 9 months Insys Therapeutics $INSY founder John Kapoor was charged with racketeering and bribery, company staffers pleaded guilty on a kickback scheme and the feds allied with company whistleblowers claiming that free dinners and entertainment were lavished on some doctors to encourage them to prescribe more of their fentanyl nasal spray.
And on Friday afternoon the FDA joined in the act, rejecting the company’s application for buprenorphine sublingual spray as a pain remedy, which the company says was due to unspecified safety concerns. The CRL highlighted the statistically significant efficacy data, Insys claimed in its statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.